Sparta, New Jersey
United States
12
2023-11-16
The entities that hold a legal rights for patent applications filed by inventor Hagner Patrick:
Patrick Hagner from Sparta, US has applied for patents for these inventions. The list has both pending applications and granted patents:
COMBINATION THERAPY FOR CANCER
#2 | 2023-01-26Therapy for the Treatment of Cancer
#3 | 2022-01-06METHODS FOR DETERMINING DRUG EFFICACY FOR THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA, MULTIPLE MYELOMA, AND MYELOID CANCERS
#4 | 2021-04-08METHODS FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA AND THE USE OF BIOMARKERS AS A PREDICTOR TO RESPONSIVENESS TO DRUGS
#5 | 2019-01-03Methods for determining drug efficacy for the treatment of diffuse large B-cell lymphoma, multiple myeloma, and myeloid cancers
#6 | 2018-08-16METHODS FOR TREATING SOLID TUMORS AND THE USE OF BIOMARKERS AS A PREDICTOR OF CLINICAL SENSITIVITY TO IMMUNOMODULATORY THERAPIES
#7 | 2017-08-24METHODS FOR TREATING SOLID TUMORS AND THE USE OF BIOMARKERS AS A PREDICTOR OF CLINICAL SENSITIVITY TO IMMUNOMODULATORY THERAPIES
#8 | 2017-06-08Cycling therapy using 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione
#9 | 2017-06-08METHODS OF TREATING DIFFUSE LARGE B-CELL LYMPHOMA USING 3-(4-AMINO-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE
#10 | 2017-03-30Methods for treating diffuse large B-cell lymphoma and the use of biomarkers as a predictor of responsiveness to drugs
#11 | 2017-02-09METHODS FOR TREATING CHRONIC LYMPHOCYTIC LEUKEMIA AND THE USE OF BIOMARKERS AS A PREDICTOR OF CLINICAL SENSITIVITY TO IMMUNOMODULATORY THERAPIES
#12 | 2016-10-27METHODS FOR DETERMINING DRUG EFFICACY FOR THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA, MULTIPLE MYELOMA, AND MYELOID CANCERS
1692588 ⎘